Business Context and Reporting Period
This Form 8-K Current Report was filed by Cortexyme, Inc. (not Quince Therapeutics, Inc.) on June 8, 2022. The filing discloses material events occurring on June 8, 2022, including the entry into a material sublease agreement, the departure of key executive officers and a director, the appointment of a new director and principal financial officer, and the results of the Annual Meeting of Stockholders.
Key Financial Metrics and Obligations
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. Specific financial obligations disclosed include:
- Sublease Rent: Base rent for the new premises is $16,692 per month for the first 12 months and $17,205.60 per month thereafter.
- Severance Payment: A cash severance payment of $354,750 (equivalent to nine months of base salary) is owed to the departing CFO/COO.
- Director Compensation: The newly appointed director is entitled to a $38,000 annual retainer and an initial stock option grant for 54,000 shares with an exercise price of $3.20.
Material Changes and Corporate Actions
Executive and Board Departures
Christopher Lowe resigned as Chief Financial Officer, Chief Operating Officer, and member of the Board of Directors. His resignation from the Board was effective immediately on June 8, 2022, while his executive roles ended on June 10, 2022. The departure was not due to any disagreement with the Company.
Executive and Board Appointments
- Principal Financial Officer: Ted Monohon, previously Chief Accounting Officer and VP of Finance, was designated as the new Principal Financial Officer on June 9, 2022.
- New Director: June Bray was appointed as a Class III director on June 9, 2022, to fill the vacancy left by Mr. Lowe.
Real Estate Agreement
The Company entered into a Sublease Agreement with ICON Clinical Research, LLC for premises in South San Francisco, California. The term runs from June 18, 2022, to November 30, 2023, with an option to extend through December 31, 2023.
Annual Meeting Results
Stockholders representing approximately 68.7% of outstanding shares voted on three proposals:
- Election of Directors: Christopher Lowe and Christopher J. Senner were elected. Notably, Mr. Lowe received 659,522 votes withheld despite his resignation occurring on the same day as the meeting.
- Ratification of Auditors: BDO USA, LLP was ratified with 20,441,558 votes for and 80,308 against.
- Executive Compensation: The advisory vote on executive compensation passed with 10,710,462 votes for and 2,437,368 against.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or specific risk factors beyond the standard disclosures regarding the separation agreement. The separation agreement includes a "change in control" provision: if the Company consummates a change in control within three months of Mr. Lowe's departure, he is entitled to additional cash severance, COBRA coverage, payment of his target annual bonus, and accelerated vesting of equity awards.
Investor Verification Checklist
- Verify the impact of the CFO/COO departure on ongoing financial reporting and operational stability.
- Review the full text of the Separation Agreement (to be filed in the Q2 2022 10-Q) for details on the change-in-control triggers.
- Monitor the transition of financial leadership under the new Principal Financial Officer, Ted Monohon.
- Assess the significance of the 659,522 votes withheld for Christopher Lowe during his election, despite his simultaneous resignation.
- Confirm the Company's cash position to ensure it can meet the $354,750 severance obligation and ongoing rent payments.